Telix's TLX591-Tx Shows Promising Safety Profile in Phase 3 Study

Event summary

  • Part 1 of Telix's ProstACT Global Phase 3 study achieved primary objectives, demonstrating an acceptable safety and tolerability profile for TLX591-Tx.
  • The study dosed 36 patients across three cohorts, combining TLX591-Tx with standard-of-care therapies: enzalutamide, abiraterone, or docetaxel.
  • No new safety signals were observed, with hematologic events aligning with expectations and being transient and manageable.
  • Telix plans to present Part 1 data to the FDA to seek an Investigational New Drug (IND) amendment for Part 2 in the U.S.
  • Part 2 of the study, a 2:1 randomized treatment expansion, is already enrolling in several countries.

The big picture

Telix's positive Phase 3 results for TLX591-Tx come at a time when targeted radiopharmaceuticals are gaining traction in oncology. The study's design, comparing TLX591-Tx with standard-of-care therapies, reflects a strategic shift towards combination treatments in metastatic castration-resistant prostate cancer (mCRPC). The company's ability to secure regulatory approvals and demonstrate clinical efficacy will be critical in differentiating TLX591-Tx in a competitive landscape.

What we're watching

Regulatory Approval
Whether the FDA will grant an IND amendment for Part 2, allowing Telix to advance the study in the U.S.
Clinical Progress
The pace at which Telix can enroll and complete Part 2 of the ProstACT Global study in approved jurisdictions.
Commercial Potential
How TLX591-Tx's differentiated safety profile and combination therapy approach will position it against existing PSMA-targeted therapies.

Related topics

Oncology